After inventing Salubria biomaterial, David N. Ku, M.D., Ph.D., President and CEO, founded SaluMedica in 1998. Dr. Ku is a Regents' Professor and Lawrence P. Huang Chair of Engineering Entrepreneurship at the Georgia Institute of Technology, and is Professor of Surgery at Emory School of Medicine. He received an M.D. from the Emory School of Medicine, a Ph.D. in Aerospace Engineering from the Georgia Institute of Technology, and a B.A. in Engineering from Harvard University. The invention of Salubria marks the first new biomaterial designed specifically for medical implants in years.

The company has integrated a compliant Quality System according to the requirements of the FDA and European International Standards Organization (ISO), allowing it to achieve ISO-9001, EN 46001 and EN ISO 13485 certification.

Just eighteen months after the Company's inception, SaluMedica's team developed its first product, the SaluBridge Nerve Cuff for peripheral nerve repair. SaluBridge received FDA market clearance for the US in late 2000, followed by the CE mark in 2001 for sale in Europe, and the Medical Device License for sale in Canada in early 2002.

The Company's second product, SaluCartilage, is designed to replace cartilage surfaces worn out by arthritis and sports injury. Damaged articular cartilage may be cored out and replaced with SaluCartilage to provide a smooth, load-bearing joint surface. This procedure offers a less invasive and more cost-effective alternative to current therapies. SaluCartilage was granted the CE Mark in April 2002, allowing for sale in Europe. The Company selected instrumentation maker Arthrex as the ideal partner to market and sell the product. The FDA submission required for sale in the US is on-going.